Late recurrence
Hormone-driven breast cancer can come back 10 or even 20 years after treatment, unlike most cancers, which is why hormone therapy lasts so long.
About half of recurrences in HR+ disease occur after year 5; risk continues at 1-2% per year to year 20 (EBCTCG, Pan 2017), driven by tumour size and nodal status. Motivates extended endocrine therapy (ATLAS, aTTom, MA.17), adjuvant CDK4/6 inhibitors for high-risk disease, and research into dormancy, ctDNA surveillance, and late-recurrence prediction assays (Breast Cancer Index).
Pages like this
not linked directly; found by shared links- PathwayThe metastatic cascade
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, Disseminated tumour cells (DTCs), What decides which disseminated cells ever colonise?, The pre-metastatic niche.
- InstitutionThe Mount Sinai Hospital / Tisch Cancer Institute
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, What decides which disseminated cells ever colonise?, Tumour dormancy.
- ProductSignatera
Shares Intercepting late recurrence with ctDNA surveillance and oral SERDs, The pre-metastatic niche, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TermHallmark: activating invasion and metastasis
Shares Disseminated tumour cells (DTCs), Tumour dormancy, MRD / molecular residual disease testing.
- PathwayIntravasation & circulating tumour cells
Shares Disseminated tumour cells (DTCs), The pre-metastatic niche, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TermMinimal / molecular residual disease (MRD)
Shares Blunt the inflammation that wakes sleeping cancer cells, Intercepting late recurrence with ctDNA surveillance and oral SERDs, Block the recycling that keeps dormant cells alive, Keep dormant cells asleep instead of trying to kill them.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.